AbbVie
ABBV | NYSE
$294.67
-$0.36 (-0.12%)
At close: Nov 16, 2026, 3:59 PM ET
$295.39
+$0.72 (+0.24%)
After-hours:
Nov 16, 2026, 7:09 PM ET
AbbVie Company Profile
Company profile explainedCompany Profile
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Key Executives
| Name | Position |
|---|---|
| Robert A. Michael | Chief Executive Officer & Chairman of the Board |
| Azita Saleki | Executive Vice President & Chief Operating Officer |
| Linda Ray | Senior VP & Chief Information Officer |
| Scott T. Reents | Executive Vice President & Chief Financial Officer |
| Demetris D. Crum | Executive Vice President & Chief Human Resources Officer |
| Elizabeth Shea | Senior Vice President of Investor Relations |
| Jeffrey Ryan Stewart | Executive Vice President & Chief Commercial Officer |
| Nicholas J. Donoghoe | Executive Vice President and Chief Business & Strategy Officer |
| Perry C. Siatis | Executive Vice President, General Counsel & Secretary |
| Roopal Thakkar | Executive Vice President of Research and Development & Chief Scientific Officer |
| Tracie Haas | Senior Vice President of Corporate Affairs |
| Wulff-Erik von Borcke | Senior Vice President & President of Oncology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | 8-K | Current Report |
| Oct 23, 2026 | 3 | Filing |
| Oct 15, 2026 | 8-K | Current Report |
| Oct 05, 2026 | 8-K | Current Report |
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Sep 03, 2026 | 8-K | Current Report |
| Aug 18, 2026 | 4 | Filing |
| Aug 18, 2026 | 8-K | Current Report |
| Aug 06, 2026 | 424B5 | Filing |
AbbVie
| Country | United States |
| IPO Date | Jan 2, 2013 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 57,000 |
| CEO | Robert A. Michael |
Contact Details
1 North Waukegan Road North Chicago,
Illinois 60064-6400 United States
Stock Details
| Ticker Symbol | ABBV |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001551152 |
| CUSIP Number | 00287Y109 |
| ISIN Number | US00287Y1091 |
| SIC Code | 2834 |
Recent News
- 7 hours ago / fool.comThese 3 Dividend Stocks Have Crushed the Market This Year. Here’s Why They Are Still Buys
- 3 days ago / fool.com3 Dividend Stocks Built for a Market Priced Like It's 1999
- 4 days ago / zacks.comHow Did AbbVie's Immunology Franchise Fare in Q3?
- 4 days ago / marketbeat.com3 Pharmaceutical Stocks That Offer Safety and Growth
- 5 days ago / zacks.comABBV Stock Rises More Than 4% in a Month: Time to Buy, Hold or Sell?
- 11 days ago / zacks.com2 Defensive Healthcare Stocks Hitting New 52-Week Highs: ABBV & LLY
- 12 days ago / 247wallst.com5 High-Yield Dividend Stocks Paying Up to 6% With Payouts Built to Last
- 13 days ago / zacks.comIs Trending Stock AbbVie Inc. (ABBV) a Buy Now?
- 13 days ago / 247wallst.comExxon Mobil Just Raised Its Dividend for the 44th Year. Here Are 3 More Wall Street Favorites
- 13 days ago / reuters.comAbbVie expands Oxford R&D facility as part of £120 million-plus investment
Add to Watchlist
Select watchlists to add or remove ABBV